Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment
- 73 Downloads
Indolent non-Hodgkin lymphomas (iNHL) are a heterogeneous group of pathologies characterized by a prolonged natural history and good response to treatment. They also have a tendency to relapse, in some cases with a worse prognosis. One of the main objectives in the newest clinical trials is to identify patients at high risk of relapse. This cannot be accomplished using only clinical prognostic scores. Detection of minimal residual disease (MRD) is effective in evaluating long-term disease response, with a strong and independent predictive value that was demonstrated in large cohorts of patients. Analysis of MRD allows patient stratification based on the risk for relapse; therefore, different therapeutic programs can be designed based on the response characteristics. This tailored therapy is already happening in current clinical trials. Limits imposed by traditional PCR-based tools are being overcome due to new molecular biology techniques like droplet digital PCR and next generation sequencing. Although these techniques are not yet standardized, they will likely increase the reliability and ensure broad applicability of MRD detection in future years.
KeywordsFL MRD Predictive value ddPCR NGS
Compliance with Ethical Standards
Conflict of Interest
Daniele Grimaldi declares that he has no conflict of interest.
Elisa Genuardi declares that she has no conflict of interest.
Martina Ferrante declares that she has no conflict of interest.
Simone Ferrero has received compensation from Janssen for service as a consultant; compensation from Janssen and Pfizer for participation on advisory boards; and compensation from Janssen, Pfizer, and Gilead for service on speakers’ bureaus.
Marco Ladetto declares, in the past 5 years, the following relationships in terms of consultancy, participation on advisory boards, invitations to scientific meetings, institutional research support, and contracts: AbbVie, Acerta, Amgen, Archigen, Celgene, ADC Therapeutics, Gilead, Novartis, Johnson & Johnson, Roche, Roche Diagnostics, Sandoz, and Takeda.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.Massimo F, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.CrossRefGoogle Scholar
- 3.Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33:2516–22.CrossRefGoogle Scholar
- 4.Nagham NO, Abolela MS, Abdelgawad MI, Ibrahim A, Mourad AF, Rezk K. Diagnostic Utility of 18F-FDG PECT/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma. Cancer Res Treat. 2016;4(5):88–95.Google Scholar
- 6.Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H. et al. Impact of [18F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012.Google Scholar
- 7.Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger A, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.CrossRefGoogle Scholar
- 16.Hirt C, Schüler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141:631–40.CrossRefGoogle Scholar
- 17.Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460–8.CrossRefGoogle Scholar
- 18.Ladetto M. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559–65.CrossRefGoogle Scholar
- 19.Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, et al. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia. 2006;20:1840–7.CrossRefGoogle Scholar
- 20.Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004–13.CrossRefGoogle Scholar
- 22.• Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122:3759–66 MRD was the most powerful and independent predictor of outcome in a phase III prospective trial.. Accumulation of MRD negative values increased the predictive value.CrossRefGoogle Scholar
- 25.Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.CrossRefGoogle Scholar
- 26.Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, et al. The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: an Italian retrospective study. Front Pharmacol. 2017;8.Google Scholar
- 27.Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, et al. Analysis of minimal residual disease in follicular lymphoma patients in Gadolin, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood. 2015.Google Scholar
- 28.• Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128:613 Preliminary data about a prospective phase III trial suggest that G-based regiment induces rapid and more effective tumor cell clearance than R-containing therapy as first line induction immunochemotherapy in FL.CrossRefGoogle Scholar
- 30.Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, et al. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/ IgH positive cells: is the end of molecular monitoring near? Leuk Res. 2006;30:1563–8.CrossRefGoogle Scholar
- 31.van Oers M, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen J, Klasa R, et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010;28:2246–52.CrossRefGoogle Scholar
- 33.Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, et al. Detection by polymerase chain reaction of residual cells with the Bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplant for B-cell lymphoma, n.d., 1993 by The American Society of Hematology edition.Google Scholar
- 35.Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, et al. Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. Exp Hematol. 34(12):1680–6.Google Scholar
- 39.Cavalli M, De Novi LA, Della Starza I, Cappelli LV, Nunes V, Pulsoni A, et al. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol. 2017;177(4):588–96.CrossRefGoogle Scholar
- 42.• Ladetto M, Bruggemann M, Ferrero S, Pepin F, Drandi D, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014. 2012a;28(6):1299–307 A straightforward comparison between PCR-based and NGS based methodologies.Google Scholar
- 43.Genuardi E, Klous P, Drandi D, Mantoan B, Monitillo L, Daniela B, et al. Targeted locus amplification (TLA): a novel next generation sequencing (NGS) technology to detect new molecular markers and monitoring minimal residual disease (MRD) in mantle cell and follicular lymphoma. Blood. 2017;130:2742.Google Scholar
- 45.Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstrom Macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–8.CrossRefGoogle Scholar
- 50.Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367:2255–6 author reply 2256-2257.Google Scholar
- 54.• Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36:689–96 With the aim to maximize treatment activity and increase the chance of durable disease control, R-CHOP should be the preferred option among the other options R-CVP and R-FM.CrossRefGoogle Scholar